Kapil Cotex Ltd (SKYBIOTECH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Kapil Cotex Ltd on NSE and BSE, with an AI summary of each filing.
Submission of Scrutinizer Report for the 43rd Annual General Meeting of Company held on 30th September, 2026
Annual General Meeting · 01 Oct 2026, 9:21 pm
Proceeding of 43rd Annual general Meeting of members of Skybiotech Healthcare Limited
Annual General Meeting · 30 Sept 2026, 9:34 pm
Outcome of 43rd Annual General Meeting of of SKYBIOTECH HEALTHCARE LIMITED held on 30th September, 2026
Annual General Meeting · 30 Sept 2026, 6:40 pm
Intimation of Notice of Annual General Meeting propose to be held on 30th September, 2026
Annual General Meeting · 05 Sept 2026, 6:36 pm
Submission of Annual Report for Financial Year 2025-2026
Others (Uncategorized) · 05 Sept 2026, 6:07 pm
Un-Audited Financial Results for the quarter ended on 30th June 2026
Financial Result · 15 Aug 2026, 2:34 am
Skybiotech Healthcare Q1FY27: Revenue Drops, Reports Net Loss Skybiotech Healthcare reported a consolidated net loss of ₹57.36 lakhs for Q1FY27 ended 30 Jun'26, versus a loss of ₹1.87 lakhs YoY. Total income fell 77% YoY to ₹55.39 lakhs from ₹242.28 lakhs. On a QoQ basis, revenue declined 72% from ₹198.35 lakhs. Total expenses stood at ₹112.75 lakhs. On a standalone basis, the company posted a net profit of ₹0.40 lakhs on total income of ₹4.92 lakhs. The Board approved the results on 14 Aug'26.
Outcome of Board Meeting dated 14th August, 2026 to considered and approved the Un-audited Financial Results of Company for the quarter ended on 30th June, 2026
Outcome · 15 Aug 2026, 2:28 am
Kapil Cotex Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 49.3 (-79.4% YoY | -73.1% QoQ) ■ EBITDA: -52.5 (Profit to Loss YoY | +40.4% QoQ) ■ EBITDA Margin (%): -106 (Profit to Loss YoY | -5829 bps QoQ) ■ PAT: -57.4 (-2967.4% YoY | -88.8% QoQ) ■ EPS (INR): -2.56 (Profit to Loss YoY | +13.5% QoQ)
Skybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Un-Audited financial ....
Intimation · 14 Aug 2026, 5:30 am
Submission of Financial Results for the Quarter and Year ended on 31st March 2026
Financial Result · 31 May 2026, 1:22 am
Skybiotech Healthcare Reports FY26 Results, Posts Widened Net Loss Skybiotech Healthcare reported consolidated results for Q4 and FY ended 31 Mar'26. For FY26, total income was ₹740.38 lakhs vs. ₹743.45 lakhs YoY, while net loss widened to ₹111.68 lakhs from ₹236.89 lakhs in FY25. For Q4FY26, the company posted a net loss of ₹30.38 lakhs on total income of ₹198.35 lakhs, compared to a loss of ₹108.31 lakhs on income of ₹83.46 lakhs in Q4FY25. The Board approved the audited financial results on 30 May'26, accompanied by an unmodified audit opinion.
Submission of Outcome of board meeting and Financial Results for the quarter and year ended on 31st March 2026
Outcome · 31 May 2026, 1:13 am
Kapil Cotex Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 183 (+79.7% YoY | +90.1% QoQ) ■ EBITDA: -88.0 (+18.9% YoY | -100.2% QoQ) ■ EBITDA Margin (%): -48.1 (+5850 bps YoY | -241 bps QoQ) ■ PAT: -30.4 (+72.0% YoY | +37.3% QoQ) ■ EPS (INR): -2.96 (+78.4% YoY | -55.8% QoQ)
Skybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Approval of Audited Results ....
Intimation · 30 May 2026, 5:30 am
Skybiotech Healthcare Board Meeting Set for May 30, 2026, to Approve Q4 & FY26 Results Skybiotech Healthcare Ltd (BSE: 512036) has scheduled a Board of Directors meeting on Sat, 30th May'26. The primary agenda is to consider and approve the audited financial results and limited review report for the fourth quarter and the full financial year ended Mar 31, 2026. The meeting will also address any other business matters with the permission of the chair. This announcement is a formal intimation as per SEBI (LODR) Regulations, 2015, and is a key precursor to the company's earnings release.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 30 Apr 2026, 9:58 pm
Skybiotech Healthcare Confirms It Is Not a "Large Corporate" Skybiotech Healthcare Ltd confirmed it does not fall under the "Large Corporate" category as per SEBI regulations for the financial year ending 31st Mar'26. The company reported outstanding borrowings of ₹0.00 Cr and does not have a credit rating. This declaration exempts it from the mandatory requirement to raise a portion of its incremental borrowings through debt securities. The filing, dated 30/Apr/26, clarifies its status, removing potential obligations under the SEBI framework for large entities.
Submission of Un-Audited Financial Results for the Quarter ended on 31st December, 2025
Financial Result · 15 Feb 2026, 12:26 am
Skybiotech Healthcare Reports Q3FY26 Consolidated Financial Results Skybiotech Healthcare reported Q3FY26 consolidated results with revenue from operations at Rs 96.27 lakhs, down 61.8% YoY from Rs 252.13 lakhs. The net loss for the quarter widened to Rs 48.47 lakhs compared to a loss of Rs 39.48 lakhs in Q3FY25. Total expenses decreased to Rs 152.59 lakhs from Rs 308.31 lakhs YoY. For the nine months ended 31st Dec'25, revenue was Rs 526.74 lakhs and net loss stood at Rs 81.30 lakhs, versus a loss of Rs 128.66 lakhs YoY.
Outcome of Board Meeting to Considered and Approved Un-Audited Financials for the Quarter ended on 31st December, 2025
Outcome · 15 Feb 2026, 12:19 am
SKYBIOTECH HEALTHCARE LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakh) ■ Revenue: 96.3 (-61.8% YoY | -49.8% QoQ) ■ EBITDA: -44.0 (-41.4% YoY | -94.3% QoQ) ■ EBITDA Margin (%): -45.7 (-3335 bps YoY | -3387 bps QoQ) ■ PAT: -24.8 (+48.3% YoY | +20.6% QoQ) ■ EPS (INR): -1.29 (+57.8% YoY | +0.0% QoQ)
Skybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Approval of Unaudited ....
Intimation · 14 Feb 2026, 5:30 am
Skybiotech Healthcare to Announce Q3 FY26 Results on 14th Feb'26 Skybiotech Healthcare Ltd (BSE: 512036) has scheduled a Board of Directors meeting on 14th Feb'26. The primary agenda is to consider and approve the unaudited financial results and limited review report for the quarter ended on 31st Dec'25. This meeting will be a key event for investors tracking the company's Q3 FY26 performance.
Revised Un-audited Financial Results for the quarter ended on 30th September, 2025
Financial Result · 21 Nov 2025, 3:33 am
Un-Audited Financial Results for quarter ended on 30th September 2025
Financial Result · 15 Nov 2025, 6:21 am
Outcome of Board Meeting held on 14th November, 2025 to Considered and approved Un-audited Financials Results for the quarter ended on 30th September, 2025
Outcome · 15 Nov 2025, 6:18 am
Kapil Cotex Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Consideration and approval of Unaudited ....
Intimation · 14 Nov 2025, 5:30 am
Receipt of Approval of Registrar of Company (ROC) for Change of Name from Kapil Cotex Limited to Skybiotech Healthcare Limited
Others (Uncategorized) · 08 Nov 2025, 7:55 pm
Scrutinizer Report of AGM
Annual General Meeting · 27 Sept 2025, 1:10 am
Proceeding of 42nd Annual General Meeting of Kapil Cotex Limited
Annual General Meeting · 25 Sept 2025, 6:16 pm
Outcome of 42nd Annual General Meeting of Kapil Cotex Limited
Annual General Meeting · 25 Sept 2025, 5:41 pm
Annual Report for Financial Year 2024-25
Others (Uncategorized) · 29 Aug 2025, 7:13 pm
Resignation of Mr. Santosh Shivaji Pimparkar-(DIN: 08466723) Executive Director of Company
Change in Management · 29 Aug 2025, 1:27 am